Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM70YTF)

Drug Name
HTS-466284 Drug Info
Synonyms
4-(3-Pyridin-2-YL-1H-pyrazol-4-YL)quinoline; 396129-53-6; LY-364947; LY364947; 4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)quinoline; 4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)QUINOLINE; TbetaR-I Inhibitor; LY 364947; ALK5 Inhibitor I; TGF-beta RI Kinase Inhibitor; 4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]quinoline; CHEMBL261454; Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor; 4-(3-pyridin-2-yl)(1h)-pyrazol-4-yl quinoline; 4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline; [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole; 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
Cross-matching ID
PubChem CID
447966
ChEBI ID
CHEMBL261454
CAS Number
CAS 396129-53-6
TTD Drug ID
D0XB4P

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
RNA transport 2.11 0.00e+0 128/186 (68.82%) EIF5;EIF2S3;RPP40;...
Ribosome biogenesis in eukaryotes 2.10 0.00e+0 52/108 (48.15%) DKC1;IMP4;RPP40;...
Aminoacyl-tRNA biosynthesis 2.04 0.00e+0 15/66 (22.73%) QRSL1;CARS2;GATC;...
DNA replication 1.88 1.14e-2 34/36 (94.44%) MCM5;PRIM1;RPA2;...
Spliceosome 1.87 1.22e-2 101/150 (67.33%) SRSF7;SRSF1;HNRNPA3;...
Ribosome 1.85 1.14e-2 113/158 (71.52%) MRPL12;MRPL4;MRPL3;...
Tyrosine metabolism 1.85 9.77e-3 30/36 (83.33%) GOT2;ADH1B;ADH5;...
RNA polymerase 1.84 1.04e-2 23/31 (74.19%) POLR1E;POLR3B;POLR1B;...
Human papillomavirus infection -1.63 3.91e-2 284/331 (85.8%) FZD3;IKBKB;ITGA9;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.65 3.86e-2 79/89 (88.76%) STAT3;MAPK13;TLR2;...
Lysosome -1.66 3.46e-2 115/128 (89.84%) LGMN;GGA3;HYAL3;...
HIF-1 signaling pathway -1.67 3.46e-2 105/109 (96.33%) LTBR;CREBBP;ELOC;...
Ferroptosis -1.68 3.32e-2 36/41 (87.8%) GPX4;SAT1;SLC3A2;...
Focal adhesion -1.69 3.17e-2 180/201 (89.55%) RAC1;LAMC1;LAMA5;...
Sphingolipid metabolism -1.69 3.16e-2 32/49 (65.31%) CERK;GLB1;UGCG;...
JAK-STAT signaling pathway -1.70 2.99e-2 146/162 (90.12%) CREBBP;EGF;IFNAR1;...
Small cell lung cancer -1.74 1.96e-2 90/92 (97.83%) LAMC1;LAMA5;GADD45B;...
Epithelial cell signaling in Helicobacter pylori infect... -1.76 1.67e-2 62/70 (88.57%) MAPK13;ATP6V1A;CASP3;...
NF-kappa B signaling pathway -1.76 1.75e-2 90/104 (86.54%) LTBR;RELB;LY96;...
PI3K-Akt signaling pathway -1.77 1.66e-2 317/354 (89.55%) PPP2R2D;ATF2;GNG11;...
Amoebiasis -1.78 1.43e-2 99/102 (97.06%) GNAQ;RAB7A;SERPINB9;...
Phagosome -1.79 1.37e-2 118/152 (77.63%) ATP6AP1;DYNC1LI1;ATP6V1B2;...
Legionellosis -1.81 1.09e-2 51/57 (89.47%) TNF;IL6;ITGB2;...
Th17 cell differentiation -1.82 1.17e-2 95/107 (88.79%) TBX21;IL1B;MAPK1;...
Protein digestion and absorption -1.83 1.08e-2 78/103 (75.73%) SLC36A1;SLC1A1;COL18A1;...
Mucin type O-glycan biosynthesis -1.83 1.17e-2 20/36 (55.56%) GALNT6;ST3GAL1;C1GALT1;...
Fluid shear stress and atherosclerosis -1.92 4.86e-3 123/139 (88.49%) IL1R2;CALML4;GSTM1;...
MicroRNAs in cancer -1.92 5.30e-3 146/310 (47.1%) APC2;ERBB3;HDAC5;...
IL-17 signaling pathway -1.93 5.83e-3 84/94 (89.36%) TNF;IL6;MAPK9;...
Th1 and Th2 cell differentiation -1.93 6.48e-3 80/92 (86.96%) TBX21;MAPK1;JAK2;...
TGF-beta signaling pathway -1.93 7.29e-3 81/94 (86.17%) SMAD2;SMAD3;SMURF2;...
Viral protein interaction with cytokine and cytokine re... -2.00 5.00e-3 84/100 (84%) CXCR3;CCR3;TNFRSF10D;...
Malaria -2.01 3.89e-3 44/50 (88%) TNF;IL6;ITGB2;...
Osteoclast differentiation -2.02 4.67e-3 117/127 (92.13%) LILRA5;AKT1;SIRPB1;...
Cytokine-cytokine receptor interaction -2.06 2.92e-3 246/295 (83.39%) IL17B;TGFB2;OSM;...
Rheumatoid arthritis -2.08 3.89e-3 78/93 (83.87%) TNF;IL6;ITGB2;...
TNF signaling pathway -2.11 5.83e-3 103/112 (91.96%) FOS;CX3CL1;PIK3CB;...
ECM-receptor interaction -2.15 0.00e+0 80/88 (90.91%) ITGB3;COL4A1;TNC;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.66uM - 10uM 6H, 24H